Adamas Pharma (ADMS): Strong Balance Sheet & Cost Containment in 3Q:16 - Mizuho
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Mizuho Securities analyst, Irina Koffler, reiterated her Buy rating on shares of Adamas Pharmaceuticals (NASDAQ: ADMS) after announcing a bottom line "beat" driven by reduced spending.
The company also disclosed a $200M shelf filing, and a potential $22.3M secondary offering at $13.91, which should bolster its balance sheet in the unlikely scenario the company decided to go it alone rather than be acquired. The analyst still views ADMS as a likely takeout target in 2017 and reiterated her $26 PT.
Shares of Adamas Pharmaceuticals closed at $13.93 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Upgrades Juniper Networks (JNPR) to Outperform
- KLR Group Raise Price Target on Oasis Petroleum (OAS) to $22; Reiterates Buy
- Newell Brands (NWL): Cutting PT - Jefferies
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Earnings
Related EntitiesIrina Koffler
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!